Inclusion Criteria:
  -  Age >18 years and <65 years old
  -  Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the Mental Health Clinic
  -  Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hour) who are non-adherent to CPAP as defined by device usage of less than 4 hours per night
  -  Chronic ( 3 months' duration) insomnia disorder
  -  Psychotherapeutic treatment stable for at least 4 weeks prior to randomization
  -  Capable of giving informed consent
Exclusion Criteria:
  -  Insomnia secondary to pain
  -  History of narcolepsy and/or cataplexy
  -  Treatment for seizure disorders
  -  Pregnant or lactating
  -  History of clinically significant hepatic impairment
  -  History of hypersensitivity, intolerance, or contraindication to eszopiclone
  -  Use of potent cytochrome p450 3A4 inhibitor medications (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication
  -  Unwilling to try or use CPAP
  -  Diagnosis of current schizophrenia or schizoaffective disorder
  -  Diagnosis of a substance dependence/abuse disorder in the past year
  -  History of complex nocturnal behaviors while using eszopiclone
  -  Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others
  -  Diagnosis of bipolar disorder
  -  Consumption of more than two alcoholic beverages per night
  -  Receiving behavioral or pharmacological treatment for insomnia including benzodiazepines